New research suggests that patients who stop using popular slimming jabs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise plans.
Research printed in a prominent health publication points out that while overweight people frequently drop about a fifth of their body weight while on the medication, the mass comes back at an estimated rate of 0.8 kg per month once they quit.
"Users buying such treatments need to be aware of the risk of quick rebound weight gain when the therapy ends," warns expert Dr. Susan Jebb.
This pace of regain implies a reversion to original mass within about 18 months.
Comparing Therapies
The study, which looked at 37 of studies involving over 9,000 of patients, compared the results of the injectable medications with conventional dieting.
The team emphasize that individuals who shed pounds through lifestyle changes alone generally experience a less rapid creep back—around 100 grams monthly—after stopping.
Explaining the Quick Regain
Doctors propose the mechanism of the jabs is key to understanding the amplified rebound.
The injections mimic a body's own chemical called GLP-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 levels far above than normal might result in the body to produce less of its endogenous hormone, and could diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' means hunger is uncontrolled, making excessive eating much more probable."
A Chronic Condition?
Health authorities suggest the jabs for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians contend that, given the likelihood of weight regain, the treatment is often long-term.
This perspective is reinforced by pharmaceutical companies, who state that the results "highlight the persistent character of excess weight," akin to managing diseases like high blood pressure.
Patient Accounts
People who have discontinued the medication describe a sudden return of hunger.
"It was like a switch flipping and you're instantly ravenous," said a patient.
The struggle is compounded if patients have not developed sustainable dietary or behavioural changes during treatment.
Widespread Adoption
Survey data show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Adoption is higher among women than men.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
Ultimately, researchers caution that while the jabs are potent agents for shedding pounds, they are not a permanent solution and long-term success relies on integrated behavioural changes.
